Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, Other, Topics

Novo Partners for Early Stage Small Molecule Development

Here is a brief preview of this blast: Novo Nordisk has formed a strategic alliance with Evotec for the discovery and development of novel small molecule compounds for the treatment of diabetes, obesity, NASH, CVD, and diabetic kidney disease. The partnership with Evotec is Novo’s 5th external R&D collaboration since the start of 2018. Financial terms of the agreement were not disclosed. Below, FENIX provides insight into Novo’s ongoing efforts to build up its early stage pipeline in adjacent therapy areas to diabetes via external partnerships.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.